You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company plans to launch a single-cell CNV assay, a single cell ATAC-seq assay, and a single-cell feature barcoding assay later this year.
The company has also developed two liquid biopsy cancer test, Liquid GPS Core for DNA and Liquid GPS Expression for RNA.
Following some major integration issues and other data challenges, Stanford is preparing to expand genomic medicine beyond rare diseases and cancer.
The Seoul-based company also recently raised $1.9 million in series B funding and is targeting between $7 million and $8 million to close the round.
The test has been validated for use with the same full set of female urogenital specimens that are used with Cobas NT/NG testing, as well as for use with male urine.
Among the firms reporting, BGI talked about plans to cut down the time and cost of its WGS service, and Invitae's CEO made a surprising proclamation about genetic testing.
Companies in the life science tools and molecular diagnostics spaces provided updates on their businesses at the 36th annual JP Morgan Healthcare Conference this week in San Francisco.
Genome Medical will use the proceeds of its Series A-1 financing to expand its nationwide footprint, as well as to invest in its telegenomics platform.
The newly launched LunaDNA hopes that its community model of compensating individuals for contributing genomic and health information will lead to better research.
The company has been working for several years under NIH grants totaling more than $7 million and is now preparing for its first formal product launch.
Los Angeles brought and settled a civil enforcement action against the makers of an at-home test for SARS-CoV-2, NPR reports.
The Guardian reports that Cancer Research UK is cutting its research funding by £44 million.
Technology Review examines factors affecting SARS-CoV-2 testing turnaround times.
In PNAS this week: mapping of ancient human migrations in Europe, recurrent gene fusion in breast cancer, and more.